VTAK VS THAR Stock Comparison
Performance
VTAK10/100
10/100
VTAK returned -27.27% in the last 12 months. Based on SPY's performance of 15.17%, its performance is below average giving it a score of 10 of 100.
THAR10/100
10/100
THAR returned -18.00% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
VTAK75/100
75/100
4 analysts offer 12-month price targets for VTAK. Together, they have an average target of 0, the most optimistic target put VTAK at 0 within 12-months and the most pessimistic has VTAK at 0.
THAR
"Analyst Price Targets" not found for THAR
Earnings
VTAK100/100
100/100
VTAK has missed earnings 0 times in the last 20 quarters.
THAR100/100
100/100
THAR has missed earnings 1 times in the last 20 quarters.
Volatility
VTAK48/100
48/100
VTAK has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
THAR50/100
50/100
THAR has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Catheter Precision, Inc. Summary
Healthcare
Medical - Devices
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
Tharimmune, Inc. Common Stock Summary
Nasdaq / THAR
Healthcare
Biotechnology
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare VTAK to other companies in the same or a similar industry.